Rhett Figliuzzi
Associate Manager, Evidence Synthesis, Value & Evidence Services
Expertise:
Rhett is an Associate Manager on Evidence Synthesis team at EVERSANA and provides support on literature reviews and other evidence synthesis projects for pharmaceuticals and medical devices.
Rhett joined EVERSANA in 2021 and has supported several evidence synthesis projects such as systematic and targeted literature reviews, feasibility assessments, meta-analyses, and manuscript development. Rhett also has some experience in reimbursement submissions and economic modelling. His experience spans several disease areas such as oncology, neurology, and auto-immune disorders.
Prior to joining EVERSANA, Rhett completed his Honours Bachelor of Medical Science in Pharmacology and Medical Cell Biology and Master of Science in Anatomy and Cell Biology at Western University. His graduate research focused on the role of ER stress, protein folding, and protein trafficking in rare, connexin-linked skin disease, and using targeted interventions to improve mutant gap junction formation.
Articles by Rhett Figliuzzi
The Importance of Quality-of-Life Metrics in mCRPC
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable nature of mCRPC, maintaining or improving quality of life (QoL) has become an important goal of therapy for patients, caregivers and physicians QoL metrics are also essential in the approval and reimbursement of cancer therapies. Quality of life can be measured using utility values, such as the EQ-5D family of instruments. The EQ-5D scales measure QoL through five dimensions of health – mobility, self-care, usual activities, pain and discomfort, and anxiety and depression – […]